J&K Bank opens
563rd branch

Excelsior Correspondent

JAMMU, July 15: The J&K Bank today opened its 563rd branch at Shiv Nagar in Udhampur ....more

Exporters move court to seek relief on maize export ban

NEW DELHI, July 15: Several exporters, affected by a ban on maize exports, have approached courts seeking permission ....more

Ranbaxy gets shareholders nod for securities issue to Daiichi

MUMBAI, July 15: Pharmaceutical firm Ranbaxy Laboratories today said it has received shareholders approval for allotment of over 7 ......more

TRAI recommends licensing regime for cable operators, MSOs

NEW DELHI, July 15: TRAI today recommended that Cable TV industry and the Multi-system operators (MSO) should be brought under licensing, a move aimed at restructuring the ...more

Sun Pharma extends date of open offer

NEW DELHI, July 15: Five days after the Israel-based Taro Pharmaceutical termed the open offer launched by Sun Pharmaceuticals as ‘sham’, the Mumbai-based firm ....more

Fitch cuts India’s credit outlook to negative from stable

NEW DELHI, July 15: Deteriorating fiscal position of the Union Government on account of increasing oil and fertiliser ....more

JWT appoints Bakshi as Global Business Director

NEW DELHI, July 15: Global advertising major JWT today announced the appointment of Jagdip Bakshi as its Global Business Director, in charge of ...more

UCO Bank scouting foreign partner for fin services arm

NEW DELHI, July 15: Kolkata-based UCO Bank is scouting for a foreign partner for its proposed subsidiary in financial services segment, in a bid to increase its fee based income."We are in the process of floating a subsidiary ......more

     
     

J&K Bank opens 563rd branch

Excelsior Correspondent

JAMMU, July 15: The J&K Bank today opened its 563rd branch at Shiv Nagar in Udhampur District in a simple function.

K K Sharma, President J&K Bank Corporate Headquarters, who was the chief guest, inaugurated the branch, while Abdul Rashid, Vice President, was also present at the inauguration ceremony.

Speaking on the occasion, Sharma reiterated the bank’s commitment towards the upliftment of general masses by empowering them financially.

Also speaking, Rashid apprised the gathering about the various schemes and financial services being offered by the bank.

Exporters move court to seek relief on maize export ban

NEW DELHI, July 15: Several exporters, affected by a ban on maize exports, have approached courts seeking permission to ship their consignments lying at ports as the prohibition covered even goods in transit.

The Commerce Ministry, in consultation with Agriculture Ministry, is devising ways to help "genuine exporters" but on a selective basis, sources said.

"Those who have letters of credit (LCs) as also the shipping bills could be considered for relaxation," an official said.

Earlier this month, the Centre had banned export of maize till October 15, to increase its availability in the domestic market and check prices of corn, poultry and other products.

While some exporters have approached the Commerce Ministry for allowing them to ship their consignments for which they have already entered into contracts with documents like shipping bill, others have moved different courts, sources said.

The Commerce Ministry is going slow on the exporters' demand for relaxation of the export ban on goods in transit because of the bitter experience of 'pulses scam' in 2007.

Last year, traders took advantage of the exception granted for goods in transit and made windfall profits by getting backdated LCs from some tax havens.

On complaints from political parties, a CBI enquiry was initiated in the 'pulses scam'.

In a circular to the customs authorities, the Directorate General of Foreign Trade has said the export ban on maize "shall not be applicable to consignments already handed over to Customs for examination and subsequent exports" up to the date of announcing the ban. (PTI)

Ranbaxy gets shareholders nod for securities issue to Daiichi

MUMBAI, July 15: Pharmaceutical firm Ranbaxy Laboratories today said it has received shareholders approval for allotment of over 7 crore securities to Japanese drug maker Daiichi Sankyo.

The shareholders of the company at the extra ordinary general meeting held today approved the allotment of 46,258,063 equity shares and 23,834,333 warrants to Daiichi Sankyo company on preferential basis, Ranbaxy said in a filing to the Bombay Stock Exchange.

Ranbaxy would issue over 4.62 crore equity shares at Rs 737 each and over 2.38 crore warrants convertible into one equity share of Rs 737 a piece, the company added.

Recently, Ranbaxy had announced that the promoters has signed a share purchase agreement with Daiichi Sankyo to sell off their entire stake of 34.8 per cent in the company to the Japanese firm for Rs 9,576.14 crore.

Meanwhile, the Japanese drug firm, has made an open offer to pick up a further 20 per cent stake in the domestic pharma major for up to Rs 6,818.65 crore.

On completion of the acquisition, the board of directors of the company would be re-constituted to comprise 10 members, of which a combination four independent and non-independent directors would be nominated by Ranbaxy, while the rest six would be named by Daiichi Sankyo.

(PTI)

TRAI recommends licensing regime for cable operators, MSOs

NEW DELHI, July 15: TRAI today recommended that Cable TV industry and the Multi-system operators (MSO) should be brought under licensing, a move aimed at restructuring the fragmented industry.

Under the proposed licence regime, the regulator suggests imposition of an entry fee of Rs 10,000-Rs 1 lakh along with cess on the cable operators.

"No person shall operate a cable television network unless he is licensed as a cable operator, said TRAI in the draft recommendations on ‘Restructuring of Cable TV Sector’."

An entry fee of Rs 10,000 has been recommended for district level Cable TV licence, while the same is Rs 1 Lakh for a state cable TV service licence. A 10 per cent administrative cess to meet the contingency needs of the Department of Posts for maintenance of records of Cable TV operators have also been proposed by the telecom regulator.

The licence would be valid for five years.

The regulator has also recommended a separate licensing provision for Multi-system Operators(MSOs), who it says should be introduced as an entity separate from Cable TV operators.

At present MSOs are registered as cable TV operator though their operations and business model are different.

The MSO’s main function is to aggregate content from different broadcasters and to provide it to the Local Cable Operators LCOs. Therefore, the regulatory framework for the MSOs should be different from LCOs.

The entry fee for district level MSO licence shall be Rs one lakh and net worth Rs 5 lakh. The entry fee for state level MSO licence has been proposed at Rs 10 lakhs and net worth at Rs 10 lakhs. (PTI)

Sun Pharma extends date of open offer

NEW DELHI, July 15: Five days after the Israel-based Taro Pharmaceutical termed the open offer launched by Sun Pharmaceuticals as ‘sham’, the Mumbai-based firm today extended the expiry date of the open offer to September 2.

Sun Pharma today said its subsidiary, Alkalodia Chemical Exclusive Group has extended the expiry date of the Tender Offer for purchase of all outstanding ordinary shares of Taro Pharmaceuticals.

The offer was previously scheduled to expire on Monday, July 28, 2008.

"The extension was recommended by Tel-Aviv court to allow the court to rule on the merits of the litigation commenced against Alkalodia...Regarding the applicability of the special tender offer rules under the Israeli law," Sun Pharma said in a statement.

Such recommendations for the extension was agreed upon by all parties to the litigation, the company said.

Last month, Sun Pharma through its subsidiary had launched a tender offer at a price of 7.75 dollar per share to acquire all outstanding ordinary shares of Taro, including the founders’ shares.

Sun claimed that Alkalodia exercised its option under the agreement to acquire all the shares held by controlling shareholders of Taro, under the option agreement signed with the company in last year’s 454-million dollar merger.

Taro has unilaterally terminated the merger agreement citing undervaluation, which Sun Pharma challenged at the New York Supreme Court. However, the Israeli company had termed the tender offer by Sun Pharma as a ‘sham’.

"It is a ‘sham’ offer, because we believe Sun knows that it will not be accepted by the shareholders," Taro said to its shareholders. (PTI)

Fitch cuts India’s credit outlook to negative from stable

NEW DELHI, July 15: Deteriorating fiscal position of the Union Government on account of increasing oil and fertiliser subsidy bill has prompted global credit rating agency Fitch to downgrade India’s credit outlook from stable to negative today.

Although the Fitch revised the outlook on Long-term Local Currency Issuer Default Rating (IDR) from stable to negative, it has retained the investment grade rating at BBB-, which indicates low credit risk.

"The revision to the local currency outlook is based on the considerable deterioration in the Central government’s fiscal position in 2008-09, combined with noticeable increase in government debt issuance to finance subsidies not captured in the Budget," said James McCormack, Asia Head of Sovereign Rating, Fitch.

The downgrade by Fitch is one of the main reasons for all-round selling in the stock markets. The benchmark equity index Sensex was down over 547 points and was ruling at around 12,782 points.

Another global rating agency Standard and Poor’s last week had said it might downgrade India’s sovereign ratings, if the country’s rising inflation, widening fiscal deficit and political instability continues in the longer term.

Fitch further pointed out that inflation has continued to accelerate despite steps taken by the RBI to tighten monetary policy.

It further said with inflation rate nearing 12 per cent, there could be further tightening of monetary policy in the days ahead.

Fitch has also forecast that India’s economic growth rate will moderate to 7.7 per cent in 2008-09 from nine per cent last fiscal. (PTI)

JWT appoints Bakshi as Global Business Director

NEW DELHI, July 15: Global advertising major JWT today announced the appointment of Jagdip Bakshi as its Global Business Director, in charge of the company's client Unilever.

The company has also promoted Ravi Dehspande as Chairman and Chief Creative Officer of its subsidiary Contract, a JWT press release said.

"Unilever is one of our most important clients and has been with JWT for over hundred years...With this appointment, we are confident that the relationship will see new highs," JWT Worldwide CEO Bob Jeffrey said.

JWT, formerly known as J Walter Thompson, is a subsidiary of the US-based Boston WPP Group.

Bakshi's new responsibilities would include client relationship management and ensuring advertising solutions in all product categories. His job will be based out of London and Bakshi would assume his new responsibilities from September this year. (PTI)

UCO Bank scouting foreign partner for fin services arm

NEW DELHI, July 15: Kolkata-based UCO Bank is scouting for a foreign partner for its proposed subsidiary in financial services segment, in a bid to increase its fee based income.

"We are in the process of floating a subsidiary in the financial services space in association with a foreign and domestic partners," UCO Bank Chairman and Managing Director S K Goel said.

The proposed venture would be a one stop shop for all financial needs of an individual. The venture, among other activities, would undertake selling insurance and mutual fund products of different companies. Besides, it would also deal in loan syndication, he said.

The state-owned bank would have 49 per cent stake in the venture while the foreign partner would have 26 per cent, as per the present regulations.

The foreign partner would bring in expertise, he said, adding, remaining stake would go to a domestic entity or entities, could be another bank or a corporate house.

It would take 4-5 months to form the venture as the bank is in process of seeking in-principle approval from the RBI and government.

The bank will shortly appoint a consultant which would help in scouting the partners as well as working out details of the project, he said.

The bank is talking to some consultants like Ernst & Young and Pricewaterhouse Coopers, he said.

On its branch expansion, Goel said the bank would open about 126 branches this year.

Currently, UCO has 1,967 branches across the country. (PTI)

Further decline in Instanex Skindia GDR index...

MUMBAI, July 15: The Instanex Skindia GDR Index declined further by 2.60 points or 0.12 per cent to 2,223.55 on July 14, 2008 from previous close of 2,226.16.

However, The P/E Ratio edged up to 18.11 from 18.10, a Instanex Capital release said here today.

Following are the GDR and ADR rates for July 14 in US dollars with differences in percentage from the previous level given in brackets.

Dr Reddy'S (ADR) 15.70 (+1.03)

GAIL (GDR) 46.00 (-3.26)

Grasim Ind (GDR) 41.50 (+1.22)

ICICI Bank (ADR) 26.29 (-1.20)

Infosys Tech (ADR) 37.15 (-2.60)

ITC (GDR) 3.95 (-3.89)

L&T (GDR) 56.00 (+2.49)

Mahindra & Mah (GDR) 12.70 (+4.96)

Ranbaxy Labs (GDR) 11.10 (-9.54)

Reliance (GDR) 97.50 (+3.25)

Satyam Comp (ADR) 22.54 (-2.30)

SBI (GDR) 58.55 (+1.95)

Sterlite Ind (ADR) 15.46 (+2.32)

Tata Communi (ADR) 17.30 (Unch)

Tata Motors (ADR) 9.30 (-0.75)

(PTI)

Glenmark’s neuropathic drug candidate ready for trials

MUMBAI, July 15: Drug maker Glenmark Pharmaceuticals today said its candidate for neuropathic, osteoarthritis and other inflammatory pain—GRC 10693, is entering phase I trials.

The molecule has been filed for phase I approval with European regulatory authorities and GRC 10693 is Glenmark’s fifth molecule to enter clinical trials, the company said in a filing to the Bombay Stock Exchange.

"...We are glad to have a Phase I ready molecule that could present a potential opportunity as it matures. We see this as further validation of strength and speed of our discovery chain," Glenmark Pharmaceuticals MD and CEO Glenn Saldanha said.

The company expects to complete phase I trials for the candidate and initiate phase II before the end of financial year 2009.

The neuropathic pain market is estimated at around five billion dollars with over 40 million patients worldwide, while the osteoarthritis market is valued at over four billion dollar with over 20 million patients.

(PTI)

Hyundai launches new i10 automatic with Kappa engine

SRIPERUMBUDUR, CHENNAI, July 15: Riding on the soaring success of new hatchback i10, Hyundai Motor India Ltd (HMIL) today launched the latest version of i10 automatic with 1.2-litre ‘Kappa’ engine.

The new four-cylinder Kappa petrol engine offers considerable benefits in refinement and performance over the original 1.1-litre with no penalty in fuel economy or emissions.

The new-generation engines will be manufactured at the new assembly plant, which is part of the company’s second phase of expansion.

"The new engine and the transmission plant, which has the capacity of 2,50,000 units per annum, has cost us over 250 million dollars," company President Ashok Jha told reporters here.

HMIL, a wholly owned subsidiary of South Korea-based Hyundai Motors, also plans to raise its annual capacity from the present six lakh units to 6.4 lakh units, he added. (UNI)

Hyundai to launch ‘i20’ by end of 2008

CHENNAI, July 15: Country’s second largest car maker Hyundai today said it will launch a new small car ‘i20’ by the end of this year, which will complete the company’s product portfolio in the compact car segment.

Besides, the company today launched a new ‘i10’, powered by a 1.2 litre Kappa engine, priced between Rs 3.99-5.43 lakh.

The proposed ‘i20’ would also be powered by 1.2 litre Kappa engine.

"The i20 will be launched by the end of 2008 and it will complete our range of product portfolio in the compact car segment," Hyundai Motor India Ltd (HMIL) Managing Director and CEO Heung Soo Lheem told reporters here.

The newly launched ‘i10’ with 1.2 litre Kappa engine would be available in three variants - Magna, Sportz and Asta.

"With the launch of these models, the contribution from Indian operation to overall global sale of Hyundai will increase to 15 per cent in a couple of years from the current 12 per cent," Lheem said, adding Hyundai Motor has become the fifth biggest car maker in the world.

On its new engine, Kappa, Lheem said: "This engine is exclusively manufactured in India only. This shows Hyundai’s commitment to make India as a global small car hub."

The company’s new engine and transmission plant in Sriperumbudur set up at an investment of 250 million dollar, would have a capacity of 2.5 lakh units per annum.

Overall, the company has invested 421 million dollar on the Kappa project over a period of 48 months.

Lheem said, the company has already received huge export orders, including 50,000 units from Europe, for the new ‘i10’.

"... But the quantum of exports will entirely depend on the domestic demand," he added.

Lheem, however, said the current 1.1 litre engine would continue to power both ‘Santro’ and ‘i10’, but the new Kappa engine would significantly raise the bar in this segment.

Since its launch eight months back, the company has sold 1.85 lakh units of ‘i10’, of which 75,000 units were sold in the domestic market.

The Korean automobile giant earlier had announced its plans to launch a small car in India by 2011, with a price tag of 3,500 dollar (about Rs 1.45 lakh), which is currently under development at its research and development centre in Korea.

By August this year, the company is planning to launch the LPG variant of its most successful model ‘Santro’. The car, powered by a 1,086cc engine, is available in CNG, diesel and petrol versions at present.

On the export front, the company targets to export two lakh units in 2008 from about one lakh units last year. It is currently exporting i10, Santro, Getz and Accent in 95 countries across the world. (PTI)



|
home | state | national | business| editorial | advertisement | sports |
|
international | weather | mailbag | suggestions | search | subscribe | send mail |